RNS Number : 7033B MaxCyte, Inc. 01 February 2024 MaxCyte, Inc. (" MaxCyte " or the "Company") Total Voting Rights ROCKVILLE, Maryland - 1 February 2024 : MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell - engineering company focused on providing enabling platform
RNS Number : 4333B MaxCyte, Inc. 31 January 2024 MaxCyte, Inc. (" MaxCyte " or the "Company") Exercise of options and PDMR dealing ROCKVILLE, MD , January 31, 2024 : MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform
RNS Number : 4077B MaxCyte, Inc. 30 January 2024 TR-1: Notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which
Wugen to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support its programs for hematologic and solid tumor cancers ROCKVILLE, Md. and ST. LOUIS, Jan. 30, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading cell-engineering focused company
RNS Number : 3812B MaxCyte, Inc. 30 January 2024 MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen's Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers Wugen to use MaxCyte's Flow Electroporation®
RNS Number : 2701B MaxCyte, Inc. 29 January 2024 TR-1: Notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which
RNS Number : 1340B MaxCyte, Inc. 29 January 2024 MaxCyte announces filing of Form 8-K ROCKVILLE, MD , January 29, 2024 - MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development
Imugene using MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support azer-cel – a potential first-in-class allogeneic CD19 CAR T product candidate for the treatment of blood cancer along with additional novel cell therapy programs ROCKVILLE, Md., and SYDNEY, Australia, Jan.
RNS Number : 6275A MaxCyte, Inc. 23 January 2024 MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs Imugene using MaxCyte's Flow Electroporation® technology and ExPERT™ platform to support azer-cel - a potential first-in-class allogeneic CD19
RNS Number : 0139Z MaxCyte, Inc. 09 January 2024 MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results ROCKVILLE, MD , January 9, 2024 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling
